Topics Webinar

Kinases, Cancer, Drugs and Artificial Intelligence

Good afternoon, and a very warm welcome to everyone joining us for today’s webinar, “Kinases, Cancer, Drugs, and Artificial Intelligence.” It is my distinct pleasure to open this session, and I want to extend a special thank you to each of you—whether you are joining from academia, the pharmaceutical industry, or clinical practice—for taking the time to be part of this important discussion.

Today, we turn our focus to a field that has become central to modern oncology: the study and therapeutic targeting of protein kinases. Over the past two decades, kinases have emerged as one of the most clinically successful classes of drug targets in cancer. These enzymes act as critical molecular switches, governing a vast network of signaling pathways that control cell proliferation, survival, and metabolism. When dysregulated—whether through mutation, overexpression, or chromosomal translocation—kinases drive the hallmark behaviors of malignancy.

It is no exaggeration to say that the discovery of kinase inhibitors has transformed the therapeutic landscape. From the groundbreaking success of imatinib in chronic myeloid leukemia to the latest generation of highly selective ATP-competitive and allosteric inhibitors, we have seen how a deep understanding of kinase biology can translate into life-saving drugs. However, we are also acutely aware of the persistent challenges: acquired resistance, off-target toxicity, and the daunting complexity of kinase signaling networks. The question is no longer simply which kinase to target, but how to target it more intelligently, more selectively, and for the right patient at the right time.

This is where artificial intelligence enters the picture, and while much of our conversation will be anchored in kinase biology, we will explore how AI is beginning to accelerate drug discovery—from structure prediction to virtual screening. Yet let us be clear: the biology remains the foundation. Our goal today is to ask how these powerful computational tools can help us navigate the complexity of the kinome and ultimately improve patient outcomes.